Lilly still boasts a robust pipeline of next-gen obesity candidates, led by retatrutide. (iStock / Getty Images Plus) Eli Lilly has put the kibosh on an early-stage obesity drug after the candidate ...

If you look at Eli Lilly's second-quarter revenues, you come away with a very clear picture of the pharmaceutical company's business. Mounjaro, Zepbound, and Foundayo account for nearly two-thirds of ...

Eli Lilly has split four times since 1986, with the latest split implemented in October 1997. Today, the company, surging in recent years thanks to the success of its GLP-1 weight loss drug Zepbound, ...

The Food and Drug Administration approved Eli Lilly's diabetes drug Mounjaro to cut down the risk of heart attack or stroke in high-risk adults with Type 2 diabetes. The approval gives consumers ...

Eli Lilly (NYSE:LLY | LLY Price Prediction) just posted one of the most impressive quarters in Big Pharma history. Revenue jumped 47.67% to $22.974 billion, Mounjaro alone did $9.943 billion, and ...

Novo Nordisk doesn't appear to have been able to shrug off its underperformance against Eli Lilly. LLY has strengthened its dominance in global market share and maintained that disconnect against NVO.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Eli Lilly said Wednesday it is suing six companies selling versions of its experimental weight-loss drug retatrutide, calling it the beginning of a concerted effort to crack down on a vast illicit ...

Eli Lilly is suing six entities that it alleges are selling black market versions of its experimental weight-loss drug retatrutide. Lilly’s lawsuits target U.S. entities selling illegal retatrutide ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Mounjaro sales jump 91% driven by international strength Higher-margin sales of blockbuster GLP-1 drugs offset lower prices Lilly narrows 2026 adjusted EPS forecast after deal-related charges Shares ...

Eligibility definitions differ across reports, particularly whether prior failure on highest approved antiobesity dose is required versus documenting discussion of all standard treatments. A one-off ...